English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Tumor immunotherapy has entered a phase of rapid development with a shift in emphasis away from classical vaccination approaches against tumor-associated antigens (TAA) towards a focus on various strategies to modify the functions of T cells, as well as to understand and modulate the immunosuppressive nature of tumor microenvironment (TME). With such a paradigm shift, recent international conferences such as "Immune Checkpoint Inhibitors (ICI) Boston" provided unparalleled depth of insights on factors that influence combination efficacy, role of TME, identification of translational biomarkers, latest preclinical modeling approaches, as well as the scientific rationale of targeting novel immune checkpoint pathways. Here I summarize some of the highlights at ICI2017.

Current Progress in Immune Checkpoint Inhibitors for Cancer Immunotherapy: A Post Event Report of ICI2017